Red Blood Cell Disorders without MCC DRG Reimbursement

DRG 812 encompasses inpatient stays for red blood cell disorders without a Major Complication or Comorbidity, including uncomplicated anemias and related hematologic conditions. Accurate grouping matters because it determines Medicare inpatient prospective payment system reimbursement levels tied to expected resource use.

DRG 812 Overview

DRG 812 covers inpatient admissions for red blood cell disorders without a Major Complication or Comorbidity and typically includes diagnoses such as uncomplicated anemia, certain hemolytic anemias, and postoperative or drug-induced red blood cell abnormalities. This Diagnosis-Related Group groups cases with similar resource use for purposes of Medicare payment and affects base payment rates and inpatient prospective payment system adjustments. Hospitals and coders must accurately assign principal and secondary diagnoses to ensure correct grouping. The classification influences reimbursement by reflecting expected resource consumption for these medical hematologic conditions.

Acute transfusion strategy trials: studies comparing restrictive versus liberal red blood cell transfusion thresholds in hospitalized patients with anemia from non-surgical causes (eg, iron-deficiency anemia, hemolytic disorders, anemia of chronic disease) to determine short-term outcomes such as hemodynamic stability, oxygenation, and length of stay. These trials typically enroll adult inpatients who meet specific hemoglobin cutoffs and assess immediate clinical responses and transfusion-related adverse events, informing safe transfusion practices. Results are directly relevant to hospital clinicians and payers because transfusion frequency and timing are major drivers of resource use, costs, and inpatient complications within this DRG.
Comparative effectiveness studies of etiologic-specific medical management: pragmatic trials or observational comparative studies evaluating different non-transfusion therapies (for example, iron supplementation routes, erythropoiesis-stimulating strategies, or immunomodulatory regimens) for discrete red blood cell disorders without major complications. These studies focus on defined subgroups such as patients with iron-deficiency anemia, autoimmune hemolytic anemia, or anemia of chronic kidney disease who are admitted for symptomatic anemia but lack major comorbid complications; outcomes include need for subsequent transfusion, readmission, functional status at discharge, and hospital resource utilization. Findings help providers choose treatments that reduce inpatient interventions and help payers predict and manage utilization patterns and coverage decisions for therapies used during the index hospitalization.
Post-discharge outcomes and care-transition research: cohort studies and interventional trials testing discharge planning, outpatient monitoring, and outpatient therapy initiation (eg, scheduled iron infusions, follow-up for hemoglobin targets, or adherence supports) to prevent readmissions and continued anemia-related morbidity. These studies enroll patients discharged after an admission for red blood cell disorders without major complications, measuring 30- and 90-day readmission rates, outpatient treatment uptake, and patient-reported outcomes. For hospitals and payers, this research identifies effective strategies to lower readmission penalties, reduce downstream costs, and improve longer-term quality metrics associated with this DRG.

Acute transfusion strategy trials: studies comparing restrictive versus liberal red blood cell transfusion thresholds in hospitalized patients with anemia from non-surgical causes (eg, iron-deficiency anemia, hemolytic disorders, anemia of chronic disease) to determine short-term outcomes such as hemodynamic stability, oxygenation, and length of stay. These trials typically enroll adult inpatients who meet specific hemoglobin cutoffs and assess immediate clinical responses and transfusion-related adverse events, informing safe transfusion practices. Results are directly relevant to hospital clinicians and payers because transfusion frequency and timing are major drivers of resource use, costs, and inpatient complications within this DRG.
Comparative effectiveness studies of etiologic-specific medical management: pragmatic trials or observational comparative studies evaluating different non-transfusion therapies (for example, iron supplementation routes, erythropoiesis-stimulating strategies, or immunomodulatory regimens) for discrete red blood cell disorders without major complications. These studies focus on defined subgroups such as patients with iron-deficiency anemia, autoimmune hemolytic anemia, or anemia of chronic kidney disease who are admitted for symptomatic anemia but lack major comorbid complications; outcomes include need for subsequent transfusion, readmission, functional status at discharge, and hospital resource utilization. Findings help providers choose treatments that reduce inpatient interventions and help payers predict and manage utilization patterns and coverage decisions for therapies used during the index hospitalization.
Post-discharge outcomes and care-transition research: cohort studies and interventional trials testing discharge planning, outpatient monitoring, and outpatient therapy initiation (eg, scheduled iron infusions, follow-up for hemoglobin targets, or adherence supports) to prevent readmissions and continued anemia-related morbidity. These studies enroll patients discharged after an admission for red blood cell disorders without major complications, measuring 30- and 90-day readmission rates, outpatient treatment uptake, and patient-reported outcomes. For hospitals and payers, this research identifies effective strategies to lower readmission penalties, reduce downstream costs, and improve longer-term quality metrics associated with this DRG.

OpenPayer

Summary & Overview

Red Blood Cell Disorders without MCC: Inpatient Reimbursement Overview

DRG 812 Overview

Clinical Trials

Related Codes

Clinical Trials

Related Codes